Skip to main content
All Posts By

admin

pills-it-sxc

Top 5 pathways to personalized medicine – Healthcare IT News

By News Archive

pills-it-sxc

If there’s one thing everyone in healthcare can probably agree on right now, it’s that there is an awful lot of data being generated each and every day. What to do with that data, however, is another question.

As Ted Driscoll, digital health director at venture capital firm Claremont Creek Ventures, sees it, the explosion of data is a definite boon for personalized medicine. Indeed, he said recently, “Medicine is becoming synonymous with big data – the data sets are just huge, now – but we had to wait for the IT revolution to happen and mature” in order to begin to put that data to use.

Read More
nih-ncats-logo

NCATS Research & Development Day – Sept. 12th

By News Archive

nih-ncats-logo

NCATS Research & Development Day will provide the unique opportunity to showcase the projects and technologies that have been incubating in a variety of NCATS drug development programs, including Therapeutics for Rare and Neglected Diseases (TRND) and Bridging Interventional Development Gaps (BrIDGs), to an audience of biopharmaceutical companies, venture capital, angel investors, foundations, and others. The object is to connect our collaborators with strategic partners that will provide financial and technical support to bring potential novel therapeutics to patients. The event will be held:

Thursday, September 12, 2013

Novartis Institutes for Biomedical Research        

Cambridge, Massachusetts

Read More
biobuzz-md-flag

BioBuzz MoCo – July 24, 2013

By News Archive

biobuzz-md-flag

When: Wednesday July 24, 2013 from 4:30 PM to 7:00 PM EDT

Where: Growlers 227 E Diamond Ave Gaithersburg, MD 20877

Join us for a co-hosted BioBuzz and Women In Bio event with our sponsor, Social & Scientific Systems, Inc., along with many others from the local biotech industry at another exciting BioBuzz event on July 24th from 4:30 – 7:00 p.m. in Gaithersburg.  Due to an overwhelming positive response to the location, we’re continuing to holding the event this month at Growlers in Old Towne Gaithersburg. We’re excited to see all of you soon, so please register today!

Read More

The Biotech IPO Phenomenon of 2013: Enjoy It While It Lasts – Xconomy

By News Archive

biobeat-xconomy

The year is only half over, but one of the biggest biotech stories of 2013 is going to be the resurgence of the biotech IPO market. It’s a good news/bad news story, depending on where you stand, and how far you look out into the future.

First, the good. The IPO surge is a vote of confidence in biotech from generalist investors who have spent years ignoring the industry. It’s good news for biotech entrepreneurs and venture capitalists who back them. A lot of money will get pumped into researching and developing drugs for diseases that have been long neglected, like Duchenne Muscular Dystrophy. Regional innovation clusters will get a boost. Many small companies will have more negotiating leverage when they talk to Big Pharma companies about acquisitions. It might spur more much-needed venture investment in biotech startups.

Read More

NINDS Phase III Investigator-Initiated Efficacy Clinical Trials (U01)

By Uncategorized

Funding Opportunity Number: PAR-13-278
Opportunity Category: Discretionary
Funding Instrument Type: Cooperative Agreement
Category of Funding Activity: Health
CFDA Number: 93.583
Eligible Applicants State governments
County governments
City or township governments
Special district governments
Independent school districts
Public and State controlled institutions of higher education
Native American tribal governments (Federally recognized)
Public housing authorities/Indian housing authorities
Native American tribal organizations (other than Federally recognized tribal governments)
Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
Private institutions of higher education
For profit organizations other than small businesses
Small businesses
Others (see text field entitled “Additional Information on Eligibility” for clarification)
Agency Name: HHS-NIH11
Closing Date: Sep 07, 2016
Award Ceiling:
Expected Number of Awards:
Creation Date: Jul 22, 2013
Funding Opportunity Description: The purpose of this Funding Opportunity Announcement (FOA) is to provide a vehicle for submitting grant applications to conduct multi-site, randomized, controlled, Phase 3 clinical trials to the National Institute of Neurological Disorders and Stroke (NINDS). The trials may address questions within the mission and research interests of the NINDS. Information about the mission and research interests of the NINDS can be found at the NINDS website (http://www.ninds.nih.gov/).

Read more http://www.grants.gov/search/search.do?mode=VIEW&oppId=238034

Read More
blood-vessels-stem-cells-jhu-hub

Johns Hopkins researchers custom-build blood vessels using stem cells – JHU Hub

By News Archive

blood-vessels-stem-cells-jhu-hub

Johns Hopkins researchers have coaxed stem cells into forming networks of new blood vessels in the laboratory, then successfully transplanted them into mice, a technique that could potentially be used to make blood vessels genetically matched to individual patients, the investigators say.

Their research results appear online this week in the Proceedings of the National Academy of Sciences.

Read More
healthbox-tech-cocktail

Healthbox Partners with Leading Nashville Stakeholders for New Accelerator

By News Archive

healthbox-tech-cocktail

Healthbox, a leading business accelerator focused on healthcare technology and technology-enabled companies, is expanding its accelerator program to Nashville this fall with anchor partner BlueCross BlueShield of Tennessee. Healthbox is strategically building local partnerships in key cities to stimulate a pipeline of new solutions, while creating a global community of leaders passionate about improving healthcare. This is the second new Healthbox location revealed in 2013; another one was launched in Boston in April, preceded by one in Chicago in 2012.

“We have been planning our entrance into this market for the last year,” says Healthbox founder and CEO, Nina Nashif. “Nashville is the Silicon Valley of healthcare and the best place for us as we continue to expand the breadth and depth of our community.”

Read More
annual-sickle-cell-meetings

Annual Sickle Cell Disease Clinical Research Meetings

By News Archive

annual-sickle-cell-meetings

Monday, August 19, 2013 – Wednesday, August 21, 2013 

Time: 7:00 a.m. – 5:00 p.m.

Location:
Natcher Conference Center
45 Center Drive
Bethesda, MD 20892

Sponsored by:
Blood Diseases Program
Division of Blood Diseases and Resources
National Heart, Lung, and Blood Institute
National Institutes of Health
Department of Health and Human Services 

Read More
nhlbi-logo-new.png

NHLBI Funding Opportunity Announcements, July 18, 2013

By News Archive

nhlbi-logo-new.png

The following funding opportunity announcements from the NHLBI or other components of the National Institutes of Health, might be of interest:

NIH Guide Notice:

NOT-OD-13-087: Notice of Change to Page Limits and Application Due Date in RFA-OD-13-008 Limited Competition: Restoring Research Resources Lost Due to Hurricane Sandy (R24)

  • The purpose of this Notice is to revise the page limits for the Research Strategy section and to extend the due date of RFA-OD-13-008.

NOT-DK-13-012: Notice to Include AIDS Application Due Dates for PA-12-179 Exploratory/Developmental Clinical Research Grants in Obesity (R21)

NOT-HL-13-184: Correction of Key Dates for PAR-13-009 Secondary Dataset Analyses in Heart, Lung, and Blood Diseases and Sleep Disorders (R21)

  • Key dates for PAR-13-009 “Secondary Dataset Analyses in Heart, Lung, and Blood Diseases and Sleep Disorders (R21) have been revised.

Requests for Applications (RFAs):

RFA-HL-14-010: Developing a Point-of-Care Device for the Diagnosis of Sickle Cell Disease in Low Resource Settings SBIR (R43/ R44)

  • This announcement encourages applications that propose to develop a point of care device for the diagnosis of sickle cell disease (SCD) in infants and young children in low-income and low-resource settings. The aim of this program is to provide rapid diagnosis of SCD to children such that appropriate therapy can be given to reduce the risk of future complications.
washington-dc-mall

D.C. region raises $418 million in second-quarter venture – Washington Business Journal

By News Archive

washington-dc-mall

The D.C. region raised $418 million in venture funding in April, May and June, according PricewaterhouseCoopers’ MoneyTree report, more than twice the total of second quarter 2012.

The “DC/Metroplex,” as defined by PWC, includes far-flung areas of Virginia and Maryland, not just the District and its suburbs. With the strong second quarter haul, the region has raised nearly as much in the first half of 2013 ($704 million) as it did all of last year ($735 million). For comparison, companies in the area raised $203 million in Q2 2012, and $286 million in the first three months of 2013.

Read More

Search

You have successfully subscribed to the newsletter

There was an error while trying to send your request. Please try again.

BioHealth Innovation will use the information you provide on this form to be in touch with you and to provide updates and marketing.